As part of the Startup SG Equity scheme, government will co-invest with independent, qualified 3rd party investors into a startup. This scheme aims to stimulate private-sector investments into innovative, Singapore-based technology startups with intellectual property and global market potential.
Startup SG Equity has different investment parameters for general tech and deep tech startups:
|General tech||Deep tech|
|Investment Cap for each startup||$2M||$4M|
|Co-investment ratio||7:3 up to $250K,
1:1 thereafter up to $2M
|7:3 up to $500K,
1:1 thereafter up to $4M
Startups and investors may apply for Startup SG Equity. Each category has its own set of eligibility criteria.
Eligibility for startups:
Startups seeking government co-investment under Startup SG Equity should meet the following criteria:
- Be a Singapore-based company with core activities carried out here.
- Be incorporated as a Private Limited company for less than five years.
- Have paid-up capital of at least $50,000.
- Be able to prove substantial innovative and intellectual content for its products and/or services and applications.
- Have high-growth potential with clear scalability for the international market.
- Have identified a ready, independent third-party investor(s).
- Business must not be involved in the following business activities: gambling, tobacco-related products, or any other activities which are in violation of law, or against public interest.
- Company cannot be a subsidiary or joint-venture.
Eligibility for third-party investors:
To be eligible for co-investment, interested individuals or corporate investors should meet the following criteria:
- The investor(s) must be able to contribute to the startup’s growth. The investor(s) should possess the management experience, relevant business contacts and/or necessary technical expertise that can value-add to the startup.
- The investor(s) must be prepared to invest at least $50,000 each into each startup.
Applicants must submit a two-page executive summary and supporting documents of the business for a first-level assessment. Email your documents to email@example.com. These documents may include:
- Business plan
- Financial statements or management accounts
- Business ACRA
- Background of potential co-investor (if available)
The following Business Angel Investors are participants in the Business Angel Scheme, now subsumed under Startup SG Equity.
|August Capital Partners|
|Mr Sameer Narula
|Supply Chain & Logistics Technology, Health and Med Tech, Nutritional Science, Data Analytics and other high growth sectors that have a regional or global impact|
|Mr Chirayu Wadke
|Internet of Things for Smart Cities
|Mr Rohit Singh
|Biomedical Sciences, Digital Convergence Technology and Services, and Sustainable Technologies (Energy, Water and Food)|
|Green Meadows Accelerator|
|Ms Margaret Ong
Tel : 8157 8515
|Clean Technology, Advanced Manufacturing & Engineering
|Mr Melvyn Yeo
Tel: 6235 3738
|Mr Vicknesh R Pillay
Tel: 6438 5616
|Internet of Things, Augmented Reality / Virtual Reality
|Mr Gavin Lee
|Advanced Manufacturing & Engineering, and Clean Technology
The following partners are participants in the Sector-Specific Accelerator (SSA) programme, now subsumed under Startup SG Equity.
CBSA is a dedicated unit under Clearbridge Accelerator Pte Ltd (“CBA”) which focuses on providing follow-on and growth capabilities to biomedical companies. CBA is an incubator and early-stage venture firm under the Technology Incubator Scheme by National Research Foundation. CBSA has established strong partnerships with leading medical research institutions, industry partners and serial medical entrepreneurs globally. CBSA has deep domain expertise and a proven track record of providing the necessary funding, key networks and operational guidance to biomedical start-ups for accelerated results.
|Name:||Johnson Chen, Managing Partner|
|Sectors:||Diagnostic systems and devices (Non-invasive diagnostics, companion diagnostics, combination products), Genomic and Sequencing Analysis, Personalized Medicine, Healthcare IT & Analytics, and Assisted living.|
Fronted by a team of senior executives who are familiar with the local biomedical industry and with experiences in commercialization, investments, and managing businesses that range from emerging start-ups to high growth SMEs, Zicom MedTacc targets to invest between 4 to 10 early stage MedTech start-ups over the next 4 years. With strong in-house capabilities and networks, Zicom MedTacc will provide leadership and mentorship to assist their investees to develop business capabilities, manage commercial negotiations, define regulatory pathways, and build meaningful business relationships within the industry. Zicom MedTacc is part of the Zicom Group, a diversified engineering and manufacturing organization with a long term strategic focus in the development of its precision engineering and technology cluster.
|Sectors:||Medical Devices, In-Vitro Diagnostics, Healthcare IT|
Venturecraft is a private investment firm and venture capital firm that provides working capital, market access assistance and other essential resources that address the business, operational and capital needs of innovative medical technology companies driven by novel and unique intellectual property. The group has established partnerships with several leading research institutions including the Singapore-MIT Alliance of Research and Technology (SMART) Innovation Center and ETPL A*STAR. Its management team and board of advisors comprise senior industry executives with diversified experience in investments, operations, product development, manufacturing, IP management, quality management and regulatory affairs. The group has a proven track record in acting as a commercialization bridge for Singapore-based companies to cross over to high-growth Asian markets such as China and Taiwan.
|Sectors:||In-vitro diagnostics, diagnostics devices, moderate to high risk medical devices, Healthcare IT and Analytics|
Med-Tech Alliance comprises two corporate investors Accuron Technologies Pte Ltd, Greatbatch Inc and an angel investor, Mr Lu Yoh-Chie, who is the Executive Chairman of Biosensors. The global presence of the Med-Tech Alliance partners offers its start-ups commercial channels into Europe, USA, and Asia via its corporate offices in those regions. The collective experience and corporate insights from Med-Tech Alliance can shorten the learning curve for start-ups in the commercialisation process. Med-Tech Alliance’s partners have existing commercial products in cardiovascular, orthopaedics, urology, diagnostics and ophthalmology.
|Sectors:||General medical device / technology|